Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer
Association and prognostic value of serum inflammation markers in patients with leukoplakia and oral cavity cancer
复制标题
DOI：
10.1515/cclm-2012-0504
复制
发表时间：
2013-06-01
影响因子：
6.8
通讯作者：
Chan, Err-Cheng
中科院分区：
文献类型：
--
作者：
Chang, Pi-Yueh;Kuo, Yung-Bin;Chan, Err-Cheng
背景：口腔癌是台湾男性第四大癌症.发展的血清生物标志物面板的早期检测和疾病monitoringis，therefore，warranted.Methods：9炎症相关的标志物进行了研究，在46例白斑，151例未经治疗的口腔鳞状细胞癌（OSCC），和111年龄和性别匹配的健康对照，使用酶联免疫吸附试验。在随后的28个月的监测OSCC患者，血清样本前瞻性收集在预定的时间间隔后完成治疗。Logistic回归分析显示基质金属蛋白酶（MMP-2）、MMP-9、C反应蛋白（CRP）、转化生长因子β 1 TGF-β 1和E-选择素在组间具有最好的区分能力，并且从对照组到OSCC组，这五种标记物有显著的升高趋势。通过结合这五个标志物，通过ROC曲线分析的曲线下面积分别为0.888和0.938，白斑和OSCC组的总体敏感性分别为67.4%和80%，特异性固定为90%。在随访期间，25例OSCC患者出现复发或继发性肿瘤。治疗后无复发患者的所有检测标志物均降低。然而，在复发患者中，白细胞介素-6，CRP和血清淀粉样蛋白A仍处于升高水平。统计学分析显示，基线时CRP >= 2 mg/L和E-选择素>= 85 ng/mL的患者复发概率最高（比值比=3.029，p
Background: Oral cavity cancer ranks as the fourth leading cancer in men in Taiwan. The development of a serum biomarker panel for early detection and disease monitoring is, therefore, warranted.Methods: Nine inflammation-associated markers were investigated in 46 patients with leukoplakia, 151 patients with untreated oral cavity squamous cell carcinoma (OSCC), and 111 age- and gender-matched healthy controls using enzyme-linked immunosorbent assay. During a subsequent 28-month surveillance of OSCC patients, serum samples were prospectively collected at predetermined intervals following the completion of therapy.Results: Logistic regression analysis showed matrix metalloproteases (MMP)-2, MMP-9, C-reactive protein (CRP), transforming growth factor-beta 1 (TGF-beta 1), and E-selectin having the best discrimination power between groups and significant elevation trends of those five markers were noted from control to OSCC. By combining those five markers, a 0.888 and 0.938 area under curve by ROC curve analysis with 67.4% and 80% overall sensitivity and fixed 90% specificity for leukoplakia and OSCC groups were demonstrated. In the follow-up period, 25 OSCC patients developed recurring or secondary tumors. All examined markers had decreased in relapse-free patients following treatment. However, in patients with relapse, interleukin-6, CRP, and serum amyloid A remained at elevated levels. Statistical analysis showed that patients with CRP >= 2 mg/L and E-selectin >= 85 ng/mL at baseline had highest probability of relapse (odds ratio=3.029, p